Cytotoxicity of Clostridium difficile toxins A and B requires an active and functional SREBP‐2 pathway

Clostridium difficile is associated with antibiotic‐associated diarrhea and pseudomembranous colitis in humans. Its 2 major toxins, toxins A and B, enter host cells and inactivate GTPases of the Ras homologue/rat sarcoma family by glucosylation. Pore formation of the toxins in the endosomal membrane enables the translocation of their glucosyltransferase domain into the cytosol, and membrane cholesterol is crucial for this process. Here, we asked whether the activity of the sterol regulatory element–binding protein 2 (SREBP‐2) pathway, which regulates the cholesterol content in membranes, affects the susceptibility of target cells toward toxins A and B. We show that the SREBP‐2 pathway is crucial for the intoxication process of toxins A and B by using pharmacological inhibitors (PF‐429242, 25‐hydroxycholesterol) and cells that are specifically deficient in SREBP‐2 pathway signaling. SREBP‐2 pathway inhibition disturbed the cholesterol‐dependent pore formation of toxin B in cellular membranes. Preincubation with the cholesterol‐lowering drug simvastatin protected cells from toxin B intoxication. Inhibition of the SREBP‐2 pathway was without effect when the enzyme portion of toxin B was introduced into target cells via the cell delivery property of anthrax protective antigen. Taken together, these findings allowed us to identify the SREBP‐2 pathway as a suitable target for the development of antitoxin therapeutics against C. difficile toxins A and B.—Papatheodorou, P., Song, S., López‐Ureña, D., Witte, A., Marques, F., Ost, G. S., Schorch, B., Chaves‐Olarte, E., Aktories, K. Cytotoxicity of Clostridium difficile toxins A and B requires an active and functional SREBP‐2 pathway. FASEB J. 33, 4883–4892 (2019). www.fasebj.org

[1]  K. Aktories,et al.  Cellular Uptake and Mode-of-Action of Clostridium difficile Toxins. , 2018, Advances in experimental medicine and biology.

[2]  Klaus Aktories,et al.  Clostridium difficile Toxin Biology. , 2017, Annual review of microbiology.

[3]  R. Gerhard Receptors and Binding Structures for Clostridium difficile Toxins A and B. , 2016, Current topics in microbiology and immunology.

[4]  A. Brass,et al.  Frizzled are colonic epithelial receptors for Clostridium difficile toxin B , 2016, Nature.

[5]  M. C. Archer,et al.  The interplay between cell signalling and the mevalonate pathway in cancer , 2016, Nature Reviews Cancer.

[6]  D. Giedroc,et al.  Crystal structure of Clostridium difficile toxin A , 2016, Nature Microbiology.

[7]  D. Giedroc,et al.  Crystal structure of Clostridium difficile toxin A. , 2016, Nature microbiology.

[8]  J. Dye,et al.  Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion , 2015, mBio.

[9]  Jinsong Sheng,et al.  Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity , 2015, Proceedings of the National Academy of Sciences.

[10]  H. Feng,et al.  Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B , 2014, Cell Research.

[11]  G. Rennert,et al.  Statins use and risk of mortality in patient with Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  T. Brummelkamp,et al.  LRP1 is a receptor for Clostridium perfringens TpeL toxin indicating a two-receptor model of clostridial glycosylating toxins , 2014, Proceedings of the National Academy of Sciences.

[13]  F. Bushman,et al.  The Major Cellular Sterol Regulatory Pathway Is Required for Andes Virus Infection , 2014, PLoS pathogens.

[14]  W. Nseir,et al.  Do statins protect against the development of Clostridium difficile-associated diarrhoea? , 2013, The Journal of antimicrobial chemotherapy.

[15]  K. Lapane,et al.  Statin use and the risk of Clostridium difficile in academic medical centres , 2012, Gut.

[16]  D. Lacy,et al.  Structural organization of the functional domains of Clostridium difficile toxins A and B , 2010, Proceedings of the National Academy of Sciences.

[17]  Constantinos Zamboglou,et al.  Clostridial Glucosylating Toxins Enter Cells via Clathrin-Mediated Endocytosis , 2010, PloS one.

[18]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[19]  I. Wang,et al.  Pharmacologic Inhibition of Site 1 Protease Activity Inhibits Sterol Regulatory Element-Binding Protein Processing and Reduces Lipogenic Enzyme Gene Expression and Lipid Synthesis in Cultured Cells and Experimental Animals , 2008, Journal of Pharmacology and Experimental Therapeutics.

[20]  K. Aktories,et al.  Structure and mode of action of clostridial glucosylating toxins: the ABCD model. , 2008, Trends in microbiology.

[21]  R. Benz,et al.  Cholesterol-dependent Pore Formation of Clostridium difficile Toxin A* , 2006, Journal of Biological Chemistry.

[22]  J. Ballard,et al.  Clostridium difficile Toxins: Mechanism of Action and Role in Disease , 2005, Clinical Microbiology Reviews.

[23]  M. Brown,et al.  A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Goldstein,et al.  Isolation of Cholesterol-requiring Mutant Chinese Hamster Ovary Cells with Defects in Cleavage of Sterol Regulatory Element-binding Proteins at Site 1* , 1998, The Journal of Biological Chemistry.

[25]  P. Espenshade,et al.  Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. , 1998, Molecular cell.

[26]  J. Goldstein,et al.  The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.

[27]  R. Collier,et al.  Protective antigen‐binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino‐ or carboxy‐terminus , 1995, Molecular microbiology.

[28]  T. Wilkins,et al.  Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.

[29]  J. Bartlett,et al.  Clostridium difficile toxin. , 1981, Pharmacology & therapeutics.